Загрузка компании
Just reported
Q3 2026 results
From Generate Biomedicines's results release of 12 ноября 2026 г.; its quarterly report has since been filed.
Revenue
Actual
4,2M $
-56 % y/y
-33 % q/qGuided
—
No guide given
EPS, GAAP
Actual
-0,68 $
Guided
—
No guide given
Operating income, GAAP
Actual
-91,5M $
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Generate Biomedicines is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B $A+
EXELExelixis, Inc.16,8B $A+
JAZZJazz Pharmaceuticals plc15,5B $A
TECHBIO-Techne Corp11,4B $A+
HALOHalozyme Therapeutics, Inc.11,4B $A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 окт. 2026 г.CBGraded C, now B
MCKMckesson Corporation4 нояб. 2026 г.BAGraded B, now A
CVSCVS Health Corp4 нояб. 2026 г.BAGraded B, now A
EWEdwards Lifesciences Corporation4 нояб. 2026 г.BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 окт. 2026 г.CAGraded C, now A
На чём зарабатывает
- Research collaboration payments100 %
Доли выручки — это оценки за six months ended June 30, 2026, а не цифры из поданной отчётности.
Что продаёт3
GB-0895
An experimental antibody that blocks thymic stromal lymphopoietin, an immune-system signal. It is being tested in late-stage trials for severe asthma.
GB-4362
An experimental medicine designed to neutralize monomethyl auristatin E, a drug used in some cancer treatments. It has entered human testing.
GB-5267
An experimental cancer treatment using modified chimeric antigen receptor T cells, immune cells altered to recognize and attack cancer. It is being developed with Roswell Park Comprehensive Cancer Center.
Кто покупает2
- Amgen, which pays for research under a collaboration agreement.
- Novartis, which pays for research under a collaboration agreement.
На чём держится и что может это сломать
От чего зависит бизнес
- 1Current revenue depends on research work under agreements with Amgen and Novartis; the company says the work under both agreements is nearing completion.
- 2Clinical research and manufacturing rely in part on outside providers, including contract research organizations and contract development and manufacturing organizations.
- 3Developing and selling medicines depends on clinical trials and regulatory approval.
Что может пойти не так
- 1GB-0895 and the other experimental medicines may not prove safe and effective in clinical trials or receive regulatory approval.
- 2The company has no medicine sales, and its current collaboration revenue depends on research agreements whose work is nearing completion.
- 3The company has ongoing operating losses and expects to need additional funding to continue research and clinical development; it may not obtain that funding on acceptable terms or at all.
Полная финансовая отчётность →
О компании Generate Biomedicines, Inc.
Generate Biomedicines uses artificial intelligence and laboratory experiments to design and test proteins that could become medicines. Its most advanced candidate is being tested in severe asthma, and it is also developing treatments for other diseases. It has no medicines approved for sale; its current revenue comes from research collaborations with drug companies.
- Штаб-квартира
- Cambridge, Massachusetts
- Год основания
- 2018
- Торгуется на
- NASDAQ
- Конец финансового года
- December 31
Построено по собственной отчётности Generate Biomedicines, Inc., поданной в Комиссию по ценным бумагам и биржам США (SEC). Цифры — как отчиталась компания, история на акцию пересчитана на сегодняшнюю базу. Это описание бизнеса — не инвестиционная рекомендация и не совет что-либо покупать или продавать.
